These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 39302433)

  • 1. New staging criteria predicting m-tor inhibitors treatment effect of renal angiomyolipoma in tuberous sclerosis complex patients.
    Wang W; Qiu D; Zhao Y; Wang Z; Wang X; Li Y; Liu Y; Liao Z; Zhang Y
    World J Urol; 2024 Sep; 42(1):532. PubMed ID: 39302433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CT characteristics predict the response to everolimus or sirolimus of renal angiomyolipomas in patients with tuberous sclerosis complex.
    Wang W; Guo H; Shi B; Sun H; Li H; Zhang Y; Cai Y
    Int Urol Nephrol; 2019 Apr; 51(4):671-676. PubMed ID: 30756282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of everolimus treatment for renal angiomyolipoma associated with tuberous sclerosis complex: an evaluation based on tumor density.
    Hatano T; Atsuta M; Inaba H; Endo K; Egawa S
    Int J Clin Oncol; 2018 Jun; 23(3):547-552. PubMed ID: 29256023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of cannabidiol on renal angiomyolipoma and subependymal giant cell tumor volume in tuberous sclerosis complex.
    Barnett JR; Grinspoon RA; Harisinghani M; Caruso PA; Thiele EA
    J Clin Neurosci; 2020 Jul; 77():85-88. PubMed ID: 32409220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment effect of mTOR-inhibition on tissue composition of renal angiomyolipomas in tuberous sclerosis complex (TSC).
    Brakemeier S; Vogt L; Adams L; Zukunft B; Diederichs G; Hamm B; Budde K; Makowski MR
    PLoS One; 2017; 12(12):e0189132. PubMed ID: 29232371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association between computed tomography attenuation value of renal angiomyolipoma associated with tuberous sclerosis complex and response to everolimus.
    Liao Z; Li J; Zhao Y; Wang Z; Wang X; Qiu D; Zhang Y
    World J Urol; 2024 Jan; 42(1):10. PubMed ID: 38183428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study.
    Su R; Huang T; Gu L; Bao Y; Liu Z; Dao P; Yao L; Hu X; Fu G; Wu J; Tricard T; Wu G; Chen M; Li C; Huang Z; Zheng B; Chen Y; Xue W; Guo G; Dong P; Huang J; Zhang J
    Cancer Med; 2024 Sep; 13(17):e70181. PubMed ID: 39279295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous low-dose everolimus shrinkage tuberous sclerosis complex-associated renal angiomyolipoma: a 48-month follow-up study.
    Wei CC; Tsai JD; Sheu JN; Chen SL; Tsao TF; Yang SH; Tsai JD
    J Investig Med; 2019 Mar; 67(3):686-690. PubMed ID: 30455224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sporadic versus Tuberous Sclerosis Complex-Associated Angiomyolipomas: Predictors for Long-Term Outcomes following Transcatheter Embolization.
    Sheth RA; Feldman AS; Paul E; Thiele EA; Walker TG
    J Vasc Interv Radiol; 2016 Oct; 27(10):1542-9. PubMed ID: 27522275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of everolimus treatment for regrown renal angiomyolipoma associated with tuberous sclerosis complex after transcatheter arterial embolization.
    Hatano T; Matsu-Ura T; Mori KI; Inaba H; Endo K; Tamari M; Egawa S
    Int J Clin Oncol; 2018 Dec; 23(6):1134-1139. PubMed ID: 30069798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial.
    Bissler JJ; Kingswood JC; Radzikowska E; Zonnenberg BA; Frost M; Belousova E; Sauter M; Nonomura N; Brakemeier S; de Vries PJ; Berkowitz N; Miao S; Segal S; Peyrard S; Budde K
    Nephrol Dial Transplant; 2016 Jan; 31(1):111-9. PubMed ID: 26156073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sirolimus and tuberous sclerosis-associated renal angiomyolipomas.
    Krischock L; Beach R; Taylor J
    Arch Dis Child; 2010 May; 95(5):391-2. PubMed ID: 20457704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization and management of facial angiofibroma related to tuberous sclerosis complex in the United States: retrospective analysis of the natural history database.
    Boggarapu S; Roberds SL; Nakagawa J; Beresford E
    Orphanet J Rare Dis; 2022 Sep; 17(1):355. PubMed ID: 36104799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microscopic Kidney Disease in Tuberous Sclerosis Complex and Treatment With mTOR Inhibition.
    Kronick J; Gabril MY; House AA
    Am J Kidney Dis; 2023 Dec; 82(6):772-775. PubMed ID: 37532078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic selective arterial embolization for renal angiomyolipomas: efficacy and evaluation of predictive factors of significant shrinkage.
    Lin L; Wang C; Pei R; Guan H; Wang J; Yang M; Tong X; Zou Y
    Int Urol Nephrol; 2018 Oct; 50(10):1765-1770. PubMed ID: 30101376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1.
    Kingswood JC; Jozwiak S; Belousova ED; Frost MD; Kuperman RA; Bebin EM; Korf BR; Flamini JR; Kohrman MH; Sparagana SP; Wu JY; Brechenmacher T; Stein K; Berkowitz N; Bissler JJ; Franz DN
    Nephrol Dial Transplant; 2014 Jun; 29(6):1203-10. PubMed ID: 24729041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Rapamycin in the treatment of renal diseases associated with tuberous sclerosis complex].
    Dun S; Zou LP; Zhang MN; Wang YY; He W; Chen HM; Hu LY; Chen XQ; Lu Q; Pang LY; Liu LY; Tang LN; Wang B
    Zhonghua Er Ke Za Zhi; 2019 Nov; 57(11):852-856. PubMed ID: 31665839
    [No Abstract]   [Full Text] [Related]  

  • 18. Analysis of serum lipid parameters predicting lipid metabolic disorders in TSC-AML patients with treatment of mTOR inhibitors.
    Wang W; Wang Z; Zhao Y; Wang X; Li H; Zhang Y
    J Clin Pharm Ther; 2022 Jul; 47(7):979-985. PubMed ID: 35229896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fate of Pediatric Renal Angiomyolipoma During mTOR Inhibitor Treatment in Tuberous Sclerosis Complex.
    Wu CQ; Wolf DS; Smith EA
    Urology; 2020 May; 139():161-167. PubMed ID: 32081671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical behavior and management of three types of renal angiomyolipomas.
    Lee KH; Tsai HY; Kao YT; Lin HC; Chou YC; Su SH; Chuang CK
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 1):162-169. PubMed ID: 29549981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.